BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
45.52
-0.28 (-0.61%)
At close: 4:02PM EDT

45.52 0.00 (0.00%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Previous Close45.80
Open46.05
Bid45.34 x 3200
Ask45.52 x 4000
Day's Range45.03 - 46.13
52 Week Range44.30 - 63.69
Volume23,488,951
Avg. Volume18,798,866
Market Cap74.378B
Beta (3Y Monthly)0.87
PE Ratio (TTM)15.12
EPS (TTM)3.01
Earnings DateApr 25, 2019
Forward Dividend & Yield1.64 (3.44%)
Ex-Dividend Date2019-04-04
1y Target Est57.80
Trade prices are not sourced from all markets
  • Watch CNBC's exclusive interview with Starboard Value CEO Jeff Smith
    CNBC Videos2 days ago

    Watch CNBC's exclusive interview with Starboard Value CEO Jeff Smith

    Jeff Smith, Starboard Value CEO, sits down with CNBC's David Faber for an exclusive interview at the 13D Monitor Active-Passive Investor Summit.

  • Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene
    CNBC Videos6 days ago

    Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene

    Celgene brings to Bristol-Myers five late-stage products that could be approved in the near term, Caforio said.

  • 'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO
    CNBC Videos6 days ago

    'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO

    Celgene brings to Bristol-Myers five late-stage products that could be approved in the near term, Caforio said.

  • Bulls bet on one energy name. Plus: where Bristol-Myers may be heading
    CNBC Videos7 days ago

    Bulls bet on one energy name. Plus: where Bristol-Myers may be heading

    "Halftime Report" trader Jon Najarian spots unusual options activity in shares of Encana and Bristol-Myers. Plus, a trade update on FedEx.

  • Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks7 hours ago

    Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

    Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Moody'syesterday

    Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade

    Moody's Investors Service ("Moody's") assigned an A2 rating to Bristol-Myers Squibb Company's ("Bristol") proposed new senior unsecured exchange note offering. The rating is under review for downgrade. There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term rating or the Prime-1 short-term rating, and these ratings remain under review for downgrade.

  • Bristol-Myers Squibb Company (NYSE:BMY): Immense Growth Potential?
    Simply Wall St.yesterday

    Bristol-Myers Squibb Company (NYSE:BMY): Immense Growth Potential?

    Looking at Bristol-Myers Squibb Company's (NYSE:BMY) earnings update in December 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by...

  • Business Wireyesterday

    Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes

    Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.

  • Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
    Zacksyesterday

    Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

    Key highlights of the past week are collaborations and pipeline updates.

  • Bill Nygren Buys Constellation, S&P Global, Sells 5 in 1st Quarter
    GuruFocus.com2 days ago

    Bill Nygren Buys Constellation, S&P Global, Sells 5 in 1st Quarter

    Bill Nygren (Trades, Portfolio), portfolio manager of the Oakmark Fund, started two positions and exited five in the first quarter, he said ahead of Securities and Exchange Commission deadlines for portfolio disclosure. Warning! GuruFocus has detected 3 Warning Sign with STZ. In a first-quarter letter released last week, Nygren discussed purchases of Constellation Brands (STZ) and S&P Global Inc. (SPGI).

  • Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
    Zacks2 days ago

    Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.

  • Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
    Motley Fool2 days ago

    Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes

    The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.

  • GuruFocus.com3 days ago

    52-Week Company Lows

    According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of UnitedHealth Group Inc. (UNH) shares has declined to close to the 52-week low of $223.22, which is 23.3% off the 52-week high of $287.94. The company has a market cap of $214.19 billion.

  • Bristol-Myers' Shareholders Vote for Celgene Acquisition
    Zacks3 days ago

    Bristol-Myers' Shareholders Vote for Celgene Acquisition

    Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.

  • Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
    Zacks3 days ago

    Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

    Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

  • GuruFocus.com4 days ago

    Stocks That Fell to 3-Year Lows in the Week of April 12

    Bristol-Myers Squibb Company (BMY), Annaly Capital Management Inc. (NLY), Newell Brands Inc. (NWL) and Mylan NV (MYL) have declined to their three-year lows. Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV. The trailing 12-month dividend yield of Bristol-Myers Squibb Company stocks is 3.53%.

  • CNBC6 days ago

    Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene

    "When the two companies come together, we'll have two growing businesses," Caforio said in an interview with "Mad Money's" Jim Cramer. It's going to be a great company, [will] create value for shareholders, [and will be] very good for patients," he said. "I'm focused and we're focused on creating value for the long term and we're getting to work on the integration ... I believe the value of the new company will be demonstrated rapidly," he says.

  • Reuters6 days ago

    Bristol-Myers says shareholders vote to approve Celgene takeover

    By Michael Erman and Svea Herbst-Bayliss NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp ...

  • TheStreet.com6 days ago

    Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

    More than 75% of Bristol-Myers shareholders voted to approve the deal, according to a preliminary tally announced by Bristol-Myers on Friday. Bristol-Myers' position took a positive turn in late March after an influential shareholder advisory group recommended investors vote in favor of the cancer drug specialist's takeover, and a key activist dropped its opposition to the deal. Institutional Shareholder Services recommended the deal, which had been challenged by key Bristol-Myers shareholders Starboard Value and Wellington Management, ahead of Friday's vote.

  • Business Wire6 days ago

    Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

    Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.

  • Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
    Zacks6 days ago

    Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

    Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

  • Financial Times7 days ago

    Bristol-Myers shareholders approve $90bn Celgene takeover

    Celgene shareholders also gave their support for the deal, which is expected to close in the third quarter but awaits US regulatory approval. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines,” Bristol-Myers chairman and chief executive Giovanni Caforio said in a statement.

  • 6 Poorly Performing Stocks in Gurus' Portfolios
    GuruFocus.com7 days ago

    6 Poorly Performing Stocks in Gurus' Portfolios

    While gurus hold positions in these companies, the share price and returns continue to fall. The company, which produces crude oil and natural gas, has a $75.32 billion market cap. The share price of $66 is 17.06% below its 52-week high and 17.27% above its 52-week low.

  • Seattle Genetics' Adcetris Progresses Well Amid Competition
    Zacks7 days ago

    Seattle Genetics' Adcetris Progresses Well Amid Competition

    Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.